They found the tissue that, unlike HER2, had little change in the immunohistochemistry score between primary and metastatic brain tissues, breast cancer brain metastases had significantly higher levels of HER3 expression (91%) than primary tumours (59%), concluding that HER3 could be a potential therapeutic target in patients with brain metastasis [82]. This evidence concerns the gene ERBB2 and breast carcinoma.